2050. Deputy Ken O'Flynn asked the Minister for Health whether her Department or HSE has conducted any international benchmarking regarding medicines waste reduction strategies in comparable EU jurisdictions; and if so, to provide details. [42487/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions asked by Ken O'Flynn .
3,835 questions match, newest first.
2051. Deputy Ken O'Flynn asked the Minister for Health whether any estimate exists of medicines dispensed under State-funded schemes but not consumed due to non-adherence, therapy change, duplication, early discontinuation, death, hospital admission, or over-prescribing; and if she will make a statement on the matter. [42488/26]
2052. Deputy Ken O'Flynn asked the Minister for Health whether the HSE intends to publish annual reports arising from the new national medicines disposal programme, including estimated financial value and environmental impact of returned medicines. [42489/26]
2053. Deputy Ken O'Flynn asked the Minister for Health whether the proposed rare disease early-access framework will include formal eligibility criteria, maximum decision timelines, independent clinical oversight arrangements, and national equity safeguards; and if she will make a statement on the matter. [42490/26]
2054. Deputy Ken O'Flynn asked the Minister for Health whether her Department has conducted any estimate of the potential annual cost exposure associated with a rare disease early-access framework; and if she will make a statement on the matter. [42491/26]
2055. Deputy Ken O'Flynn asked the Minister for Health whether any ethical or legal review has been conducted regarding prioritisation criteria within the proposed early-access framework for rare diseases; and if she will make a statement on the matter. [42492/26]
2056. Deputy Ken O'Flynn asked the Minister for Health whether patient registries or national prevalence datasets will form part of the planned rare disease reimbursement reforms; and if she will make a statement on the matter. [42493/26]
2058. Deputy Ken O'Flynn asked the Minister for Health whether the absence of any national clinical audit relating to procedures funded under the Treatment Abroad Scheme since 2020 is considered acceptable from a patient-safety and governance perspective; and if she will make a statement on the matter. [42505/26]
2059. Deputy Ken O'Flynn asked the Minister for Health whether her Department or the HSE has conducted any risk assessment regarding the absence of national clinical outcome auditing for procedures funded under the treatment abroad scheme; and if she will make a statement on the matter. [42506/26]
2060. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains any mechanism to systematically monitor complication rates, revision procedures, adverse outcomes, readmissions, or long-term follow-up care requirements arising from procedures funded under the Treatment Abroad Scheme; and if she will make a statement on the matter. [42507/26]
2061. Deputy Ken O'Flynn asked the Minister for Health whether any national framework exists governing post-treatment outcome monitoring for patients returning to Ireland following procedures funded under the Treatment Abroad Scheme; and if she will make a statement on the matter. [42508/26]
2062. Deputy Ken O'Flynn asked the Minister for Health whether the HSE National Centre for Clinical Audit has ever been requested by her Department, the HSE, or the Treatment Abroad Scheme to consider conducting a national clinical audit relating to procedures funded under the Treatment Abroad Scheme; and if she will make a statement on the matter. [42509/26]
2063. Deputy Ken O'Flynn asked the Minister for Health whether any official within her Department or the HSE holds responsibility for assessing whether procedures funded under the Treatment Abroad Scheme should be subject to national clinical audit or outcome monitoring; and if she will make a statement on the matter. [42510/26]
2064. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains any standardised national framework for measuring the effectiveness or value for money of agency-supported clinics, additional theatre sessions, diagnostics initiatives or insourcing arrangements; and if she will make a statement on the matter. [42512/26]
2065. Deputy Ken O'Flynn asked the Minister for Health whether regional performance and planning divisions use uniform metrics when monitoring waiting-list reduction initiatives; if so, to provide those metrics; and if she will make a statement on the matter. [42513/26]
2066. Deputy Ken O'Flynn asked the Minister for Health whether any comparative analysis has been undertaken between hospitals or regions regarding the cost-effectiveness of additional sessions or agency-supported waiting-list initiatives since 2020; and if she will make a statement on the matter. [42514/26]
2067. Deputy Ken O'Flynn asked the Minister for Health whether the HSE can identify the total number of waiting-list removals attributable specifically to insourcing, agency-supported clinics, weekend sessions or additional diagnostics capacity in each year from 2020 to 2026; and if she will make a statement on the matter. [42515/26]
2068. Deputy Ken O'Flynn asked the Minister for Health whether the Comptroller and Auditor General, Internal Audit, or any external body has assessed the governance, monitoring, or value-for-money arrangements relating to waiting-list reduction initiatives supported by agencies or third-party providers; and if she will make a statement on the matter. [42516/26]
2175. Deputy Ken O'Flynn asked the Minister for Health the total expenditure on agency staffing in each of the years 2023, 2024, 2025 and to date in 2026. [43156/26]
2176. Deputy Ken O'Flynn asked the Minister for Health whether the HSE records the actual hourly rates paid to agency providers by grade and specialty; and if so, if she will provide a breakdown. [43157/26]
2177. Deputy Ken O'Flynn asked the Minister for Health the reason the HSE does not maintain a central cost comparator database for agency staffing expenditure. [43158/26]
2178. Deputy Ken O'Flynn asked the Minister for Health whether her Department has assessed the value-for-money implications of the HSE not maintaining a central database comparing agency staffing costs with directly employed staff costs. [43159/26]
2179. Deputy Ken O'Flynn asked the Minister for Health the amount paid annually in agency fees, commissions and VAT associated with agency staffing in each of the years 2023, 2024, 2025 and to date in 2026. [43160/26]
2180. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has any plans to establish a national agency workforce cost monitoring framework; and if so, the timeline for implementation. [43161/26]
2181. Deputy Ken O'Flynn asked the Minister for Health the top 20 agency suppliers by expenditure in each of the years 2023, 2024 and 2025. [43162/26]